Jazz Pharmaceuticals Completes Acquisition of Orphan Medical

Palo Alto, CA - June 27, 2005

Jazz Pharmaceuticals, Inc. announced today that it has completed the previously announced acquisition of Orphan Medical, Inc.

"The addition of Orphan Medical's products and experienced specialty sales force establishes our commercial presence in our neurology and psychiatry franchises," said Robert Myers, Executive Vice President and Chief Business Officer of Jazz Pharmaceuticals. "We are excited about continuing the clinical development of Xyrem(R), and we look forward to growing our commercial activities, both through acquiring additional products and by launching products from our internal product development pipeline."

In connection with the acquisition of Orphan Medical, Jazz Pharmaceuticals completed an $80 million senior debt financing led by Lehman Brothers Principal Investments. Other participants in the financing included General Electric Pension Trust, Deep Cove Mezzanine, LLC and certain entities related to Oak Hill Advisors and Oak Hill Investment Management, respectively. Jazz Pharmaceuticals has raised a total of $345 million in equity and debt funding since its formation in 2003.

About Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals is focused on helping patients by meeting unmet medical needs in neurology and psychiatry with important and innovative therapeutic products. Jazz Pharmaceuticals is aggressively building its product portfolio through a combination of commercialization and development activities. Based in Palo Alto, California, the company is committed to working closely with patients, patient advocacy groups and healthcare professionals. For further information, please visit www.jazzpharmaceuticals.com.

Contact

Matthew Fust, Chief Financial Officer, of Jazz Pharmaceuticals,Inc., +1-650-496-3777, or ; or Karen L. Bergman,+1-650-575-1509, or Michelle Corral, +1-415-794-8662, both of BCC Partners,for Jazz Pharmaceuticals, Inc. mediainfo@jazzpharma.com